All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SEFA-1024
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SEFA-1024
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020
Details:
SEFA-1024 is a novel chemically modified fatty acid derived from naturally occurring fatty acid EPA. Phase 1 trial will evaluate the safety, tolerability, and pharmacokinetics of SEFA-1024 in 96 otherwise healthy volunteers with high plasma triglyceride levels.